论文部分内容阅读
美国临床肿瘤学学会(ASCO)的降低乳腺癌 风险战略技术评价:他莫西芬和雷洛昔芬 (raloxifene),已于近期的临床肿瘤学杂志上发表。它清楚地突出了罗氏和阿斯特拉捷利康的枸橼酸他莫西芬Nolvadex(R)在降低高危妇女乳腺癌发生率和确诊为乳腺癌妇女的治疗方面所起的独特作用。此技术评价也澄清了有关雷洛昔芬用途的混乱,指出,推荐在临床试验环境之外用雷洛昔芬来降低发展乳腺癌的风险还为时过早,因为它的疗效证据有限。ASCO指出,此技术评价是对有关激素药物不仅用于治疗乳腺癌,而且也用于降低乳腺癌发生风险的新资料的第一个重要独立性评论。
The American Academy of Clinical Oncology (ASCO) Strategy for the Reduction of Breast Cancer Risk: Tamoxifen and raloxifene, published in the recent issue of Clinical Oncology. It clearly highlights the unique role played by Roche and AstraZeneca’s Tamoxifen Citrate Nolvadex(R) in reducing the incidence of breast cancer in high-risk women and in the treatment of women diagnosed with breast cancer. This technical evaluation also clarified the confusion about the use of raloxifene and pointed out that it is premature to recommend that raloxifene be used outside the clinical trial environment to reduce the risk of developing breast cancer because of limited evidence of its efficacy. ASCO pointed out that this technical evaluation is the first important independent review of new data on hormone drugs not only for the treatment of breast cancer, but also for reducing the risk of breast cancer.